Skip to main content

Year: 2024

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty.DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical industry, spanning leadership, sales, and marketing roles in both large and smaller organizations. She also brings valuable experience within...

Continue reading

Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024

GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 31, 2024 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company’s website, within Investors Relation section, at https://ir.brbiotech.com. The AGM will be held for the following proposals:as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending...

Continue reading

CLICK announced to expand service to the Community Care Service Voucher scheme for elderly (CCSV scheme) in Hong Kong

– CLICK will collaborate with Care U Professional Nursing Service Limited, being the first non-NGOs private company to become a licensed recognized service provider under the CCSV scheme, to provide integrated Home-based service for elderly under scheme in Hong Kong  – The CCSV scheme is a government-sponsored program that provides community care services through a “money-following-the-user” and “affordable users pay” subsidy model. Hong Kong, Dec. 03, 2024 (GLOBE NEWSWIRE) — Click Holdings Limited (“Click Holdings” or “we” or “our”, NASDAQ: CLIK) and its subsidiaries (collectively, the “Company”), signed a cooperation agreement with Care U Professional Nursing Service Limited (“Care U”) and agreed to jointly provide integrated Home-based service for elderly under the CCSV scheme in Hong Kong. The...

Continue reading

Financial calendar 2025 for the companies of the Nykredit Group

To Nasdaq Copenhagen                                    3 December 2024 Financial calendar 2025 for the companies of the Nykredit Group 5 FebruaryPublication of Annual Reports 2024 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group. 20 MarchAnnual General Meeting of Totalkredit A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 20 MarchAnnual General Meeting of Nykredit Bank A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 20 MarchAnnual General Meeting of Nykredit Realkredit A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 8 MayPublication of Q1 Interim Report 2025 of the Nykredit Realkredit Group. 13 AugustPublication of H1 Interim Reports 2025 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group. 6 NovemberPublication...

Continue reading

Financial calendar 2025 for the companies of the Nykredit Group

To Nasdaq Copenhagen                                3 December 2024 Financial calendar 2025 for the companies of the Nykredit Group 5 FebruaryPublication of Annual Reports 2024 and announcements of Financial Statements of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group. 20 MarchAnnual General Meeting of Totalkredit A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 20 MarchAnnual General Meeting of Nykredit Bank A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 20 MarchAnnual General Meeting of Nykredit Realkredit A/S, Kalvebod Brygge 1-3, DK-1780 Copenhagen V. 8 MayPublication of Q1 Interim Report 2025 of the Nykredit Realkredit Group. 13 AugustPublication of H1 Interim Reports 2025 of the Nykredit Realkredit Group, Totalkredit A/S (in Danish only) and the Nykredit Bank Group. 6 NovemberPublication...

Continue reading

Fortuna reports progress on its share buyback program

VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) is pleased to report that during the fourth quarter as of Friday, November 29, 2024, it has repurchased under the Company’s normal course issuer bid (NCIB) an aggregate of 6,402,640 common shares on the open market of the New York Stock Exchange. Shares were repurchased at a weighted-average price of $4.77 per common share for a total gross amount of $30,529,066, excluding brokerage fees; these shares will be cancelled. To date, the Company has repurchased 41.88 percent of the 15,287,201 shares it is authorized to repurchase under the NCIB (refer to Fortuna news release dated April 30, 2024).   Jorge A. Ganoza, Chief Executive Officer of Fortuna commented, “With record earnings in the third quarter, and strong free cash flow...

Continue reading

Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.

Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW Therapeutics Progresses first clinical use of Medigene’s End-to-End Platform to generate potentially best-in-class TCRsPlanegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced a USD $1 million milestone payment from Regeneron Pharmaceuticals, Inc. was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition of 2seventy bio Inc.’s pre-clinical and clinical oncology and autoimmune cell therapy pipeline, which closed in April 2024. The payment was triggered by a development milestone for a trial in China led by JW Therapeutics...

Continue reading

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

— First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX:1801) today jointly announce that the New Drug Application (“NDA”) for the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) has been granted conditional approval in China for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (“pMMR”) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation. This approval follows the priority review status and breakthrough therapy designation by the National Medical Products Administration (“NMPA”)...

Continue reading

Agreement to Establish Digital Currency Investment Company Partnership

SHANGHAI, Dec. 03, 2024 (GLOBE NEWSWIRE) — MultiMetaVerse Holdings Limited (NASDAQ: MMV) (“MMV” or the “Company”), a leading animation and entertainment company for young consumers in China, announced that it has reached an agreement with Zhao Mingwei (“Big Bear”) and Li Yuanfeng to jointly establish a joint – venture in Hong Kong, leveraging their respective resources to Bitcoin and Bitcoin mining machines. According to the agreement, MMV will hold 80% of the shares of the to-be-formed joint – venture company, Zhao Mingwei will hold 10% of the shares, and Li Yuanfeng will hold the remaining 10%. The board of directors will be composed of executives appointed by the three parties. The new company will purchase Bitcoin and purchase Bitcoin mining machines. The joint venture company plans to achieve Party B and Party...

Continue reading

Allot Announces its New Service Gateway Tera III for Top Tier Telecom Operators

The highest capacity multiservice platform on the market. Hod Hasharon, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) — Allot Ltd. (NASDAQ: ALLT) (TASE: ALLT), a leading global provider of innovative network intelligence and security-as-a-service (SECaaS) solutions for communication service providers (CSPs) and enterprises, today announced that it has developed the Allot Service Gateway (SG) Tera III multiservice platform. At 2.8 Tbps, the new SG-Tera III will be the highest capacity multiservice gateway platform in the telecommunications market. “The Allot SG-Tera III is truly a breakthrough for Allot and the telecommunications industry. It will easily meet the capacity, scalability and requirements of the world’s largest CSPs who want to deliver superior QoE and security services to their customers,” said Moti Goldshtein, Vice President...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.